Loading clinical trials...

COMPLETED

AMPED Outcomes Registry of Post-ED Pain Management

Acute Management of Pain From the Emergency Department: A National, Emergency Department-Based Prospective Post-Intervention Registry of Non-Opioid and Opioid Management of Acute Pain

NCT01626235•Radnor Registry Research, Inc

View on ClinicalTrials.gov

Summary

Study aims to assess patient-recorded outcomes of pain control medications prescribed in the ER after visits for specific painful injuries/illnesses.

Detailed Description

Multicenter, observational, prospective, out-of-hospital registry collecting clinical, satisfaction, quality of life, and healthcare resource utilization from subjects discharged after ED care for a specific acute pain syndrome with a clinician-determined analgesic regimen. Subjects are stratified by diagnosis and by regimen based on the treating clinician's judgment. The registry study is independent of ED care and clinician's decision-making.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Eligible subjects will meet the following criteria:
•1. Eligible diagnoses:
•musculoskeletal etiologies: acute extremity fractures sprains/strains acute gouty arthritis visceral etiologies: renal colic dysmenorrhea
•2. Age GTE 18 years;
•3. Decision to discharge from ED to community already made;
•4. Decision to give SPRIX, opioid, OR SPRIX + opioid rescue already made;
•5. Treating clinician deems patient appropriate for continued analgesic management as an outpatient for the next 3-5 days;
•6. Patient has ready touch-tone (mobile or land line) telephone access, provides number (and back-up number, if possible) and agrees (verbal or written consent as mandated by site) to answer and comply with brief IVR questionnaires daily for next 4 days.

Exclusion Criteria

•Eligible subjects will meet none of the following criteria:
•1. Patient admitted or placed on observation status from ED;
•2. Patient unwilling or unable to comply with telephonic follow-up;
•3. Fracture that requires surgical repair (even if at a later date);
•4. Patient has diagnosis of any chronic pain syndrome;
•5. Patient already routinely takes NSAID or opioid agent;
•6. Treating clinician has reasonable suspicion of drug-seeking behavior or noncompliance;
•7. Nasal abnormality or illness that could affect the absorption of intranasal medication (such as: nasal discharge, rhinitis, acute upper respiratory infection, acute epistaxis, nasal polyp, nasal tumor).

Locations (11)

University of Alabama at Birmingham

Birmingham, Alabama, United States

LSU Medical Center

New Orleans, Louisiana, United States

University of Mississippi Medical Center

Jackson, Mississippi, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Oklahoma HSC

Tulsa, Oklahoma, United States

Pennsylvania Hospital

Philadelphia, Pennsylvania, United States

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Ben Taub General Hospital

Houston, Texas, United States

Key Dates

Start Date

July 1, 2012

Primary Completion Date

March 1, 2014

Completion Date

March 1, 2014

Last Updated

March 12, 2014

Enrollment

843

ACTUAL participants

Conditions

Soft Tissue InjuriesGouty ArthritisFracturesUreteral ColicDysmenorrhea

Fibulink Syndesmosis Repair System With Early Full-Weight Bearing

NCT06085586

Ankle FracturesBimalleolar Fractures+5 more

View study

RECRUITINGPHASE4

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

NCT06565910

Femoral Neck FracturesFemur Head Necrosis+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

AMPED Outcomes Registry of Post-ED Pain Management

Inclusion Criteria

Exclusion Criteria

Fibulink Syndesmosis Repair System With Early Full-Weight Bearing

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

Sacral ESPB vs. PENG Block for Hip Hemiarthroplasty Analgesia

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures

Naringenin Supplementation in Bone Fracture Patients